Analytical Data
-
基因名
HLA-A*02:01&B2M&EBV EBNA(FMVFLQTHI) Monomer
- Application
-
别名
HLA-A*0201 & B2M & EBV EBNA (FMVFLQTHI)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&FMVFLQTHI
-
分子量
41-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/EBV EBNA (FMVFLQTHI) monomeric recombinant protein is critical for advancing our understanding of immune recognition and response to Epstein-Barr Virus (EBV) infections, which are linked to various cancers and other diseases. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a pivotal role in presenting peptide antigens to CD8+ T cells. The EBV EBNA (Epstein-Barr Nuclear Antigen) peptide, specifically FMVFLQTHI, is recognized by cytotoxic T lymphocytes (CTLs, a key component of the immune system), highlighting its potential as a target for immunotherapy. By developing a monomeric form of this complex, researchers aim to facilitate structural and functional studies that enhance the understanding of peptide-HLA interactions. This knowledge is not only crucial for vaccine development and therapeutic strategies against EBV-associated malignancies but also provides insights into peptide presentation mechanisms and CTL activation. The recombinant protein can serve as a valuable tool in assessing T cell responses in various clinical settings, fostering advancements in personalized medicine and cancer immunotherapy.
